Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials

PURPOSE: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspn...

Descripción completa

Detalles Bibliográficos
Autores principales: Rennard, Stephen I, Sun, Shawn X, Tourkodimitris, Stavros, Rowe, Paul, Goehring, Udo M, Bredenbröker, Dirk, Calverley, Peter M A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075954/
https://www.ncbi.nlm.nih.gov/pubmed/25018629
http://dx.doi.org/10.2147/COPD.S55738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075954/
https://www.ncbi.nlm.nih.gov/pubmed/25018629
http://dx.doi.org/10.2147/COPD.S55738

Ejemplares similares